Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Multiple Sclerosis – Current Treatment – Current Treatment: Physician Insights – Multiple Sclerosis (US)
Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, and many of them are next-generation alternatives within existing classes…
Major Depressive Disorder (DSM-V) – Epidemiology – Epidemiology – Major Depressive Disorder (DSM V) – Mature Markets
Clarivate Epidemiology’s coverage of major depressive disorder (MDD) (DSM-V) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets. We report…
Ovarian Cancer – Unmet Need – Unmet Need – Advanced Platinum-Sensitive Ovarian Cancer (US/EU)
The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s…
Growth Hormone Deficiency – Executive Insights – Growth hormone deficiency: Executive Insights (US)
Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often…
